Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
Ro today announced it is working with Eli Lilly and Company to streamline access to Zepbound® (tirzepatide) single-dose vials ...
"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of ...
BofA analyst Allen Lutz notes Ro Health, a direct competitor to Hims & Hers (HIMS), announced that the company is working with Eli Lilly ...
Eli Lilly has partnered with direct-to-consumer health-care startup Ro to offer more affordable single-dose vials of its ...
Shares of Hims & Hers Health Inc. slid to a three-week low on Wednesday before recovering some losses, even as retail ...